FDA approves supplemental new drug application for Novartis therapy Gilenya™ to include data showing reduction in T1 lesions in MS, a marker of disease activity
Source URL: https://qa1.novartis.us/news/media-releases/fda-approves-supplemental-new-drug-application-novartis-therapy-gilenyatm-include-data-showing-reduction-t1-lesions-ms-marker-disease-activity-0
List of links present in page
- https://qa1.novartis.us/news/media-releases/fda-approves-supplemental-new-drug-application-novartis-therapy-gilenyatm-include-data-showing-reduction-t1-lesions-ms-marker-disease-activity-0